Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1109413

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1109413

NA Stem Cell Therapy Market - Industry Trends and Forecast to 2029

PUBLISHED:
PAGES: 151 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

The North America stem cell therapy market is projected to register a substantial CAGR of 8.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029

Market Segmentation:

North America Stem Cell Therapy Market, Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (U.S., Canada) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the North America stem cell therapy market are:

The rise in the incidence of chronic diseases in the U.S.

Growth in research and development

Market Players:

Some of the major players operating in the North America stem cell therapy market are:

Osiris Therapeutics, Inc. (A subsidiary of Smith+Nephew)

Orthofix Medical Inc.

Takeda Pharmaceutical Company Limited

U.S. Stem Cell, Inc.

BrainStorm Cell Limited

International Stemcell Corporation

Athersys, Inc.

BioRestorative Therapies, Inc.

JCR Pharmaceuticals Co., Ltd

ANTEROGEN.CO., LTD

MEDIPOST

Mesoblast Ltd

PHARMICELL Co., Ltd.

STEMPEUTICS RESEARCH PVT LTD

TABLE OF CONTENTS

1 INTRODUCTION 19

  • 1.1 OBJECTIVES OF THE STUDY 19
  • 1.2 MARKET DEFINITION 19
  • 1.3 OVERVIEW OF THE NORTH AMERICA STEM CELL THERAPY MARKET 20
  • 1.4 CURRENCY AND PRICING 22
  • 1.5 LIMITATIONS 22
  • 1.6 MARKETS COVERED 22

2 NORTH AMERICA STEM CELL THERAPY MARKET: SEGMENTATION 24

  • 2.1 MARKETS COVERED 24
  • 2.2 GEOGRAPHICAL SCOPE 25
  • 2.3 YEARS CONSIDERED FOR THE STUDY 26
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 27
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
  • 2.6 MULTIVARIATE MODELLING 31
  • 2.7 PRODUCT SEGMENT LIFELINE CURVE 31
  • 2.8 DBMR MARKET POSITION GRID 32
  • 2.9 VENDOR SHARE ANALYSIS 34
  • 2.10 MARKET END USER COVERAGE GRID 35
  • 2.11 SECONDARY SOURCES 36

3 EXECUTIVE SUMMARY 37

4 PREMIUM INSIGHTS 41

  • 4.1 PESTEL 42
  • 4.2 PORTER'S FIVE FORCES MODEL 43

5 EPIDEMIOLOGY 44

6 PIPELINE ANALYSIS FOR THE NORTH AMERICA STEM CELL THERAPY MARKET 45

7 NORTH AMERICA STEM CELL THERAPY MARKET: REGULATIONS 46

8 MARKET OVERVIEW 49

  • 8.1 DRIVERS 51
    • 8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 51
    • 8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH 52
    • 8.1.3 GROWING BIOTECHNOLOGY SECTOR 53
    • 8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES 54
    • 8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES 54
  • 8.2 RESTRAINTS 55
    • 8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH 55
    • 8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY 55
    • 8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH 56
    • 8.2.4 AVAILABILITY OF ALTERNATIVES 56
  • 8.3 OPPORTUNITIES 57
    • 8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 57
    • 8.3.2 RISE IN HEALTHCARE EXPENDITURE 57
    • 8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 58
  • 8.4 CHALLENGES 58
    • 8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY 58
    • 8.4.2 STRINGENT REGULATIONS 59

9 NORTH AMERICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE 61

  • 9.1 OVERVIEW 62
  • 9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS 65
  • 9.3 PLACENTAL/UMBILICAL STEM CELL 65
  • 9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS 66
  • 9.5 OTHERS 67

10 NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE 69

  • 10.1 OVERVIEW 70
  • 10.2 ALLOGENEIC STEM CELL THERAPY 73
    • 10.2.1 MUSCULOSKELETAL DISORDERS 74
    • 10.2.2 WOUNDS AND INJURIES 74
    • 10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 74
    • 10.2.4 SURGERIES 74
    • 10.2.5 GASTROINTESTINAL DISEASES 74
    • 10.2.6 OTHER APPLICATION 74
  • 10.3 AUTOLOGOUS STEM CELL THERAPY 74
    • 10.3.1 CARDIOVASCULAR DISEASES 76
    • 10.3.2 GASTROINTESTINAL DISEASES 76
    • 10.3.3 OTHER APPLICATION 76

11 NORTH AMERICA STEM CELL THERAPY MARKET, BY APPLICATION 77

  • 11.1 OVERVIEW 78
  • 11.2 MUSCULOSKELETAL DISORDERS 80
  • 11.3 WOUNDS AND INJURIES 81
  • 11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 82
  • 11.5 SURGERIES 83
  • 11.6 GASTROINTESTINAL DISEASES 84
  • 11.7 CARDIOVASCULAR DISEASES 84
  • 11.8 OTHER APPLICATION 85

12 NORTH AMERICA STEM CELL THERAPY MARKET, BY END USER 87

  • 12.1 OVERVIEW 88
  • 12.2 HOSPITAL AND SURGICAL CENTERS 91
  • 12.3 THERAPEUTIC COMPANIES 91
  • 12.4 SERVICES COMPANIES 92
  • 12.5 OTHERS 93

13 NORTH AMERICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL 94

  • 13.1 OVERVIEW 95
  • 13.2 DIRECT TENDER 99
  • 13.3 THIRD PARTY DISTRIBUTORS 99

14 NORTH AMERICA STEM CELL THERAPY MARKET, BY REGION 101

  • 14.1 NORTH AMERICA 102
    • 14.1.1 U.S. 108
    • 14.1.2 CANADA 110

15 NORTH AMERICA STEM CELL THERAPY MARKET: COMPANY LANDSCAPE 112

  • 15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 112

16 SWOT ANALYSIS 113

17 COMPANY PROFILE 114

  • 17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021) 114
    • 17.1.1 COMPANY SNAPSHOT 114
    • 17.1.2 REVENUE ANALYSIS 114
    • 17.1.3 COMPANY SHARE ANALYSIS 115
    • 17.1.4 PRODUCT PORTFOLIO 115
    • 17.1.5 RECENT DEVELOPMENT 115

  • 17.2 JCR PHARMACEUTICALS CO., LTD ( (2021) 116
    • 17.2.1 COMPANY SNAPSHOT 116
    • 17.2.2 REVENUE ANALYSIS 116
    • 17.2.3 COMPANY SHARE ANALYSIS 117
    • 17.2.4 PRODUCT PORTFOLIO 117
    • 17.2.5 RECENT DEVELOPMENTS 117
  • 17.3 ORTHOFIX MEDICAL INC. (2021) 118
    • 17.3.1 COMPANY SNAPSHOT 118
    • 17.3.2 REVENUE ANALYSIS 118
    • 17.3.3 COMPANY SHARE ANALYSIS 119
    • 17.3.4 PRODUCT PORTFOLIO 119
    • 17.3.5 RECENT DEVELOPMENTS 119
  • 17.4 MEDIPOST (2021) 121
    • 17.4.1 COMPANY SNAPSHOT 121
    • 17.4.2 REVENUE ANALYSIS 121
    • 17.4.3 COMPANY SHARE ANALYSIS 122
    • 17.4.4 PRODUCT PORTFOLIO 122
    • 17.4.5 RECENT DEVELOPMENTS 122
  • 17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021) 124
    • 17.5.1 COMPANY SNAPSHOT 124
    • 17.5.2 REVENUE ANALYSIS 124
    • 17.5.3 COMPANY SHARE ANALYSIS 125
    • 17.5.4 PRODUCT PORTFOLIO 125
    • 17.5.5 RECENT DEVELOPMENT 125
  • 17.6 CORESTEM, INC. (2021) 126
    • 17.6.1 COMPANY SNAPSHOT 126
    • 17.6.2 REVENUE ANALYSIS 126
    • 17.6.3 PRODUCT PORTFOLIO 127
    • 17.6.4 RECENT DEVELOPMENT 127
  • 17.7 PHARMICELL CO., LTD. (2021) 128
    • 17.7.1 COMPANY SNAPSHOT 128
    • 17.7.2 PRODUCT PORTFOLIO 128
    • 17.7.3 RECENT DEVELOPMENTS 128
  • 17.8 ANTEROGEN.CO., LTD (2021) 129
    • 17.8.1 COMPANY SNAPSHOT 129
    • 17.8.2 PRODUCT PORTFOLIO 129
    • 17.8.3 RECENT DEVELOPMENTS 129

  • 17.9 ATHERSYS, INC.(2021) 130
    • 17.9.1 COMPANY SNAPSHOT 130
    • 17.9.2 REVENUE ANALYSIS 130
    • 17.9.3 PRODUCT PORTFOLIO 131
    • 17.9.4 RECENT DEVELOPMENTS 131
  • 17.10 BRAINSTORM CELL LIMITED (2021) 132
    • 17.10.1 COMPANY SNAPSHOT 132
    • 17.10.2 PRODUCT PORTFOLIO 132
    • 17.10.3 RECENT DEVELOPMENTS 132
  • 17.11 BIORESTORATIVE THERAPIES, INC. (2021) 134
    • 17.11.1 COMPANY SNAPSHOT 134
    • 17.11.2 REVENUE ANALYSIS 134
    • 17.11.3 PRODUCT PORTFOLIO 135
    • 17.11.4 RECENT DEVELOPMENTS 135
  • 17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021) 136
    • 17.12.1 COMPANY SNAPSHOT 136
    • 17.12.2 PRODUCT PORTFOLIO 136
    • 17.12.3 RECENT DEVELOPMENTS 136
  • 17.13 INTERNATIONAL STEMCELL CORPORATION (2021) 138
    • 17.13.1 COMPANY SNAPSHOT 138
    • 17.13.2 REVENUE ANALYSIS 138
    • 17.13.3 PRODUCT PORTFOLIO 139
    • 17.13.4 RECENT DEVELOPMENT 139
  • 17.14 MESOBLAST LTD (2021) 140
    • 17.14.1 COMPANY SNAPSHOT 140
    • 17.14.2 REVENUE ANALYSIS 140
    • 17.14.3 PRODUCT PORTFOLIO 141
    • 17.14.4 RECENT DEVELOPMENTS 141
  • 17.15 PLURISTEM INC.(2021) 142
    • 17.15.1 COMPANY SNAPSHOT 142
    • 17.15.2 REVENUE ANALYSIS 142
    • 17.15.3 PRODUCT PORTFOLIO 143
    • 17.15.4 RECENT DEVELOPMENT 143
  • 17.16 STEMPEUTICS RESEARCH PVT LTD 144
    • 17.16.1 COMPANY SNAPSHOT 144
    • 17.16.2 PRODUCT PORTFOLIO 144
    • 17.16.3 RECENT DEVELOPMENTS 144

  • 17.17 U.S. STEM CELL, INC. (2021) 146
    • 17.17.1 COMPANY SNAPSHOT 146
    • 17.17.2 REVENUE ANALYSIS 146
    • 17.17.3 PRODUCT PORTFOLIO 147
    • 17.17.4 RECENT DEVELOPMENT 147

18 QUESTIONNAIRE 148

19 RELATED REPORTS 151

LIST OF TABLES

  • TABLE 1 NORTH AMERICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 59
  • TABLE 2 NORTH AMERICA BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 60
  • TABLE 3 NORTH AMERICA PLACENTAL/UMBILICAL STEM CELL IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 61
  • TABLE 4 NORTH AMERICA ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 62
  • TABLE 5 NORTH AMERICA OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 63
  • TABLE 6 NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 67
  • TABLE 7 NORTH AMERICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 68
  • TABLE 8 NORTH AMERICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 69
  • TABLE 9 NORTH AMERICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 70
  • TABLE 10 NORTH AMERICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 70
  • TABLE 11 NORTH AMERICA STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 75
  • TABLE 12 NORTH AMERICA MUSCULOSKELETAL DISORDERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 76
  • TABLE 13 NORTH AMERICA WOUNDS AND INJURIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 77
  • TABLE 14 NORTH AMERICA ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 78
  • TABLE 15 NORTH AMERICA SURGERIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 78
  • TABLE 16 NORTH AMERICA GASTROINTESTINAL DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 79
  • TABLE 17 NORTH AMERICA CARDIOVASCULAR DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 80
  • TABLE 18 NORTH AMERICA OTHER APPLICATION IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 81
  • TABLE 19 NORTH AMERICA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 85
  • TABLE 20 NORTH AMERICA HOSPITAL AND SURGICAL CENTERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 86
  • TABLE 21 NORTH AMERICA THERAPEUTIC COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 87
  • TABLE 22 NORTH AMERICA SERVICES COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 88
  • TABLE 23 NORTH AMERICA OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 88
  • TABLE 24 NORTH AMERICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 93
  • TABLE 25 NORTH AMERICA DIRECT TENDER IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 94
  • TABLE 26 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 95
  • TABLE 27 NORTH AMERICA STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 101
  • TABLE 28 NORTH AMERICA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 101
  • TABLE 29 NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 101
  • TABLE 30 NORTH AMERICA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 101
  • TABLE 31 NORTH AMERICA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 102
  • TABLE 32 NORTH AMERICA STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 102
  • TABLE 33 NORTH AMERICA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 102
  • TABLE 34 NORTH AMERICA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 102
  • TABLE 35 U.S. STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 103
  • TABLE 36 U.S. STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 103
  • TABLE 37 U.S. ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 103
  • TABLE 38 U.S. AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 103
  • TABLE 39 U.S. STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 104
  • TABLE 40 U.S. STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 104
  • TABLE 41 U.S. STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 104
  • TABLE 42 CANADA STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 105
  • TABLE 43 CANADA STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 105
  • TABLE 44 CANADA ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 105
  • TABLE 45 CANADA AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 105
  • TABLE 46 CANADA STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 106
  • TABLE 47 CANADA STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 106
  • TABLE 48 CANADA STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 106

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA STEM CELL THERAPY MARKET : SEGMENTATION 18
  • FIGURE 2 NORTH AMERICA STEM CELL THERAPY MARKET: DATA TRIANGULATION 21
  • FIGURE 3 NORTH AMERICA STEM CELL THERAPY MARKET: DROC ANALYSIS 22
  • FIGURE 4 NORTH AMERICA STEM CELL THERAPY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 23
  • FIGURE 5 NORTH AMERICA STEM CELL THERAPY MARKET: COMPANY RESEARCH ANALYSIS 23
  • FIGURE 6 NORTH AMERICA STEM CELL THERAPY MARKET: INTERVIEW DEMOGRAPHICS 24
  • FIGURE 7 NORTH AMERICA STEM CELL THERAPY MARKET: DBMR POSITION GRID 26
  • FIGURE 8 NORTH AMERICA STEM CELL THERAPY MARKET: VENDOR SHARE ANALYSIS 28
  • FIGURE 9 NORTH AMERICA STEM CELL THERAPY MARKET: END USER COVERAGE GRID 29
  • FIGURE 10 NORTH AMERICA STEM CELL THERAPY MARKET: SEGMENTATION 33
  • FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA STEM CELL THERAPY MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 34
  • FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN CLINICAL TRIALS, GMP CERTIFICATION AND PRODUCT APPPROVALS IS EXPECTED TO DRIVE THE NORTH AMERICA STEM CELL THERAPY MARKET FROM 2022 TO 2029 35
  • FIGURE 13 PRODUCT TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA STEM CELL THERAPY MARKET FROM 2022 & 2029 35
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA STEM CELL THERAPY MARKET 44
  • FIGURE 15 NUMBER AND AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA IN 2022 45
  • FIGURE 16 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020 46
  • FIGURE 17 NORTH AMERICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2021 56
  • FIGURE 18 NORTH AMERICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION) 57
  • FIGURE 19 NORTH AMERICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, CAGR (2022-2029) 57
  • FIGURE 20 NORTH AMERICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE, LIFELINE CURVE 58
  • FIGURE 21 NORTH AMERICA STEM CELL THERAPY MARKET: BY TYPE, 2021 64
  • FIGURE 22 NORTH AMERICA STEM CELL THERAPY MARKET: BY TYPE, 2022-2029 (USD MILLION) 65
  • FIGURE 23 NORTH AMERICA STEM CELL THERAPY MARKET: BY TYPE, CAGR (2022-2029) 65
  • FIGURE 24 NORTH AMERICA STEM CELL THERAPY MARKET: BY TYPE, LIFELINE CURVE 66
  • FIGURE 25 NORTH AMERICA STEM CELL THERAPY MARKET: BY APPLICATION, 2021 72
  • FIGURE 26 NORTH AMERICA STEM CELL THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION) 73
  • FIGURE 27 NORTH AMERICA STEM CELL THERAPY MARKET: BY APPLICATION, CAGR (2022-2029) 73
  • FIGURE 28 NORTH AMERICA STEM CELL THERAPY MARKET: BY APPLICATION, LIFELINE CURVE 74
  • FIGURE 29 NORTH AMERICA STEM CELL THERAPY MARKET: BY END USER, 2021 82
  • FIGURE 30 NORTH AMERICA STEM CELL THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION) 83
  • FIGURE 31 NORTH AMERICA STEM CELL THERAPY MARKET: BY END USER, CAGR (2022-2029) 83
  • FIGURE 32 NORTH AMERICA STEM CELL THERAPY MARKET: BY END USER, LIFELINE CURVE 84
  • FIGURE 33 NORTH AMERICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021 90
  • FIGURE 34 NORTH AMERICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 91
  • FIGURE 35 NORTH AMERICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 91
  • FIGURE 36 NORTH AMERICA STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 92
  • FIGURE 37 NORTH AMERICA STEM CELL THERAPY MARKET: SNAPSHOT (2021) 97
  • FIGURE 38 NORTH AMERICA STEM CELL THERAPY MARKET: BY COUNTRY (2021) 98
  • FIGURE 39 NORTH AMERICA STEM CELL THERAPY MARKET: BY COUNTRY (2022 & 2029) 98
  • FIGURE 40 NORTH AMERICA STEM CELL THERAPY MARKET: BY COUNTRY (2021 & 2029) 99
  • FIGURE 41 NORTH AMERICA STEM CELL THERAPY MARKET: BY PRODUCT TYPE (2022-2029) 99
  • FIGURE 42 NORTH AMERICA STEM CELL THERAPY MARKET: COMPANY SHARE 2021 (%) 106
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!